Trial Outcomes & Findings for App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer (NCT NCT05502302)

Last Updated: 2024-07-03

Results Overview

Number of Interviews completed to help identify themes to develop a cancer-specific, multi-tiered activity/trip classification system to organize cancer treatment-related activities and trips in the app; and user stories to describe what the users want to do with the proposed app. 45-minute interviews.

Recruitment status

COMPLETED

Target enrollment

23 participants

Primary outcome timeframe

7 months

Results posted on

2024-07-03

Participant Flow

Participant milestones

Participant milestones
Measure	Cancer Patients Patients will supply examples of logistic toxicity and how they would like to measure and communicate logistic toxicity across scenarios.
Overall Study STARTED	23
Overall Study COMPLETED	15
Overall Study NOT COMPLETED	8

Reasons for withdrawal

Reasons for withdrawal
Measure	Cancer Patients Patients will supply examples of logistic toxicity and how they would like to measure and communicate logistic toxicity across scenarios.
Overall Study Lost to Follow-up	6
Overall Study Death	2

Baseline Characteristics

App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cancer Patients n=23 Participants Patients will supply examples of logistic toxicity and how they would like to measure and communicate logistic toxicity across scenarios.
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	16 Participants n=5 Participants
Age, Categorical >=65 years	7 Participants n=5 Participants
Sex: Female, Male Female	13 Participants n=5 Participants
Sex: Female, Male Male	10 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	21 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	2 Participants n=5 Participants
Race (NIH/OMB) White	17 Participants n=5 Participants
Race (NIH/OMB) More than one race	3 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants
Region of Enrollment United States	23 participants n=5 Participants

PRIMARY outcome

Timeframe: 7 months

Outcome measures

Outcome measures
Measure	Cancer Patients n=23 Participants Patients will supply examples of logistic toxicity and how they would like to measure and communicate logistic toxicity across scenarios.
Interviews	20 Interviews

PRIMARY outcome

Timeframe: 7 months

Participants with overall satisfaction with proposed system design will be measured using a 5-point Likert scale from not at all satisfied to very satisfied. The primary endpoint will be the proportion of participants who report an overall satisfaction score of 4.0 or above. 10-Minutes.

Outcome measures

Outcome measures
Measure	Cancer Patients n=15 Participants Patients will supply examples of logistic toxicity and how they would like to measure and communicate logistic toxicity across scenarios.
Satisfaction Score Follow-Up Survey	80 Percentage of participants

Adverse Events

Cancer Patients

Serious events: 0 serious events

Other events: 0 other events

Deaths: 2 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Rachel Vogel

University of Minnesota, Masonic Cancer Center

Phone: 612-624-6928

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place